Efficacy of caffeine supplementation on fatigue in patients with multiple sclerosis: A randomized double-blind placebo-controlled trial
Baghbanian SM, Gharanjik A, Ghazaeian M, Bakhshi A, Hosseinnataj A
Multiple sclerosis and related disorders · 1 cita
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-12-08 · Mult Scler Relat Disord · vol. 106 · pág. 106923
- Editorial
- Elsevier BV
- Citado
- 1 cita · más que el 73% de estudios similares · 0.6× el promedio de su campo
- Referencias
- 25 trabajos
- Acceso
- De pago
- Áreas de investigación
- Multiple Sclerosis Research Studies · Coffee research and impacts · Coenzyme Q10 studies and effects
- Palabras clave
- multiple sclerosis, fatigue, caffeine supplementation, quality of life, Multidimensional Fatigue Inventory, SF-36, mood, adverse events, tolerability
- MeSH
- humans, multiple sclerosis, fatigue, caffeine, central nervous system stimulants, severity of illness index, double-blind method, quality of life, adult, middle aged, female, male
5 autores
- Seyed Mohammad Baghbanian🇮🇷 · autor de correspondenciaMazandaran University of Medical Sciences
- Aida Gharanjik🇮🇷 · autor de correspondenciaMazandaran University of Medical Sciences
- Monireh Ghazaeian🇮🇷 · autor de correspondenciaMazandaran University of Medical Sciences
- Atieh Bakhshi🇮🇷 · autor de correspondenciaMazandaran University of Medical Sciences
- Abolfazl Hosseinnataj🇮🇷 · autor de correspondenciaMazandaran University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Fatigue represents a significant clinical challenge in patients with multiple sclerosis (MS). Existing pharmacological interventions often demonstrate limited efficacy and may be associated with adverse effects. This study investigates the potential of caffeine to mitigate fatigue and enhance quality of life (QoL) in individuals diagnosed with MS.
Methods
In a randomized, double-blind, placebo-controlled study, individuals with multiple sclerosis and self-reported fatigue were administered either 100 mg of oral caffeine daily or a placebo over 12 weeks. The primary endpoint was the severity of fatigue, as assessed by the Multidimensional Fatigue Inventory (MFI-20). Secondary endpoints included quality of life, as measured by the SF-36, and the monitoring of adverse events throughout the study duration.
Results
A clinical trial involving sixty participants was conducted. The group administered caffeine exhibited a statistically significant decrease in MFI-20 scores relative to baseline (P < 0.001) and compared to the placebo group (Mean difference of -8.55, P < 0.009). Furthermore, statistically significant improvements were noted across multiple domains of the SF-36, specifically in vitality, pain, emotional well-being, and physical functioning (P<0.05). Caffeine was well-tolerated among participants, with no serious adverse events reported.
Conclusion
Caffeine supplementation results in a significant reduction in fatigue and an improvement in quality of life and mood among patients with MS, with a favorable safety profile. These results suggest that caffeine may be a practical, readily available, and cost-effective therapeutic option for fatigue associated with MS.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.